Dr. Siefker-Radtke discusses current research on the use of erdafitinib to treat urothelial carcinoma


"In a phase 2 clinical trial, we saw that erdafitinib had an objective response rate of around 40% in patients who received prior chemotherapy for their metastatic disease," says Dr. Siefker-Radtke.

Arlene O. Siefker-Radtke, MD, is a professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. In this interview, Siefker-Radtke discusses the ongoing trials on the use of erdafitinib to treat FGFR3 altered urethelial cancers. She was interviewed during the 2022 LUGPA Annual Meeting in Chicago, Illinois.

Related Videos
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Bottle of white pills | Image Credit: © leighannef - stock.adobe.com
Illustration of AI | Image Credit: © Tierney - stock.adobe.com
DNA illustration | Image Credit: © BillionPhotos.com - stock.adobe.com
Mara R. Holton, MD, answers a question during a Zoom video interview
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.